Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Files Emergency Motion To Block Zarxio's Launch

This article was originally published in Scrip

Executive Summary

Amgen has asked the US Court of Appeals for the Federal Circuit to block next week's launch of a biosimilar of the firm's human granulocyte colony-stimulating factor Neupogen (filgrastim) until the judges have considered the company's motion for a rehearing and, if granted, review of its lawsuit against Novartis unit Sandoz.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts